AstraZeneca gives rare diseases new challenge
1 year, 9 months ago

AstraZeneca gives rare diseases new challenge

China Daily  

Visitors gather at AstraZeneca's booth during the fifth China International Import Expo in Shanghai in November. United Kingdom-based global pharmaceutical company AstraZeneca has integrated more than 10 molecular products worldwide in the rare diseases field and is promoting more than 20 clinical research programs, said an executive of the company. The company will continue to introduce new product portfolios over the upcoming five years after announcing joining the rare diseases realm in 2021, said Hu Yiqing, vice-president of AstraZeneca China and head of its rare diseases business unit, in an interview with China Daily ahead of the International Rare Diseases Day, which fell on Tuesday this year. Besides acceleration in bringing new therapies, Hu said the company will also contribute to building a more complete diagnosis and treatment system regarding rare diseases. Hu said AstraZeneca will help strengthen multidisciplinary treatment capability at the medical centers as rare diseases are usually diagnosed jointly by doctors from various backgrounds.

China Rare Rare Diseases Company Diseases Astrazeneca  therapies  astrazeneca  rare  hu  company  challenge  treatment  medical  research  china  gives  diseases

History of this topic

AstraZeneca announces plans for new innovations for China
2 months, 3 weeks ago

AstraZeneca announces plans for new innovations for China

China Daily  

Sharon Barr, executive vice-president of biopharmaceuticals R&D at AstraZeneca, delivers a speech at AstraZeneca R&D China Science Day held in Shanghai from Friday to Saturday. Announcing Shanghai as a global strategic site for the company in February, AstraZeneca currently has over 200 projects in its R&D pipeline in China, which plays an important part in the company's overall blueprint of …

AstraZeneca staff detained in China amid claims of illegal drug imports
3 months, 2 weeks ago

AstraZeneca staff detained in China amid claims of illegal drug imports

The Telegraph  

Five AstraZeneca staff have been detained in China amid claims of potential illegal activity at the British drug giant. Authorities in Shenzhen, China, are investigating how the company collected patient data, according to Bloomberg, as well as investigating the imports of a liver cancer drug yet to be approved in China. A spokesman for AstraZeneca said: “We are aware a …

Foreign firms expand investment in nation
3 months, 3 weeks ago

Foreign firms expand investment in nation

China Daily  

A view of the booth of Zeiss Group during an expo in Shanghai. Despite global foreign direct investment exhibiting a contraction trend in 2023 due to factors such as sluggish economic growth and geopolitical tensions, China's inbound investment flow remained relatively high in the past decade, said a report released on Wednesday. In the first half of 2024, multinational companies …

Med-tech of China gaining popularity
7 months, 1 week ago

Med-tech of China gaining popularity

China Daily  

AstraZeneca, a United Kingdom-headquartered pharmaceutical company, showcases its cutting-edge products and solutions at the sixth China International Import Expo. While taking strides to go global, China's medical technology sector has shown signs of overtaking and leading the world in some fields, such as cell therapy, gene editing, various medical equipment and certain cancer treatments, said a senior executive of a …

China's medical technology shows world-leading signs in some fields
7 months, 1 week ago

China's medical technology shows world-leading signs in some fields

China Daily  

AstraZeneca and five Wuxi-based local innovative biomedical enterprises release a collaborative overseas plan in Wuxi, Jiangsu province, on Friday. A large proportion of business in those areas are from overseas markets, said Leon Wang, executive vice-president, international and China president at AstraZeneca during a media interview at the seventh AstraZeneca China Ecosystem Conference held in Wuxi city, Jiangsu province, from …

AstraZeneca returning for sixth successive expo
1 year, 1 month ago

AstraZeneca returning for sixth successive expo

China Daily  

AstraZeneca, a United Kingdom-headquartered pharmaceutical company, showcases its cutting-edge products and solutions at the sixth China International Import Expo. CHINA DAILY By participating in the China International Import Expo for the sixth successive year with cutting-edge healthcare products and solutions, AstraZeneca, a United Kingdom-headquartered global pharmaceutical company, is underlining its unwavering commitment to the Chinese market. During the expo, the …

AstraZeneca plots to sell AI drug unit to the Chinese
1 year, 6 months ago

AstraZeneca plots to sell AI drug unit to the Chinese

The Telegraph  

AstraZeneca’s pioneering artificial intelligence research centre could fall into foreign ownership under reported plans for the drugs giant to spin off and separately list its Chinese division. The Chinese division owns the company’s global research and development centre in Shanghai, as well as an “AI innovation centre” being developed there. There is a lot of investment, a lot of new …

AstraZeneca inks pact with Research Society for Study of Diabetes in India
4 years ago

AstraZeneca inks pact with Research Society for Study of Diabetes in India

Live Mint  

Drug firm AstraZeneca India on Thursday said it has signed a memorandum of understanding with the Research Society for Study of Diabetes in India for driving awareness of diabetes among people to prevent complications arising from its uncontrolled incidence. As a key facet of this association, the company has unveiled a three-year patient awareness programme, 'Beyond Sugar', developed to benefit …

Discover Related